Gene therapy for X-linked retinoschisis

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study evaluates the safety and tolerability of ATSN-201, a gene therapy, in male patients aged 6 years and older diagnosed with RS1-associated X-linked retinoschisis. Participants will receive a one-time subretinal injection of ATSN-201 in one eye, and the effects will be monitored over a period of five years. The study aims to determine how well the treatment is tolerated and its safety profile in this specific patient population.

Why it matters

Who can join: the full rules

Part A and B:

Inclusion Criteria:

1. Age ≥ 18 for Cohorts 1 through 4, and age ≥ 6 years and \< 18 years for Cohort 5.
2. Male patients with clinical diagnosis of XLRS caused by mutations in RS1.
3. Best corrected visual acuity (BCVA) in study eye of 34 to 73 Early Treatment Diabetic Retinopathy Study (ETDRS) letters (corresponding to a Snellen acuity of 20/200 to 20/40).
4. Presence of foveal schisis and /or parafoveal/perifoveal schisis in the study eye on SD-OCT per the Principal Investigator.

Exclusion Criteria:

1. Pre-existing eye conditions in the study eye that would contribute significantly to an increased risk of visual loss from a subretinal injection (eg, advanced glaucoma, optic neuropathy, uveitis, corneal transplants).
2. Any intraocular surgery (including laser treatment) in the study eye within 6 months prior to Screening or any intraocular surgery anticipated in the study eye during the first 12 months of the study.
3. Treatment in a prior ocular gene or cell therapy study.

Part C:

Inclusion Criteria:

Note: For patients ineligible for bilateral dosing based on the ocular exclusion criteria, the same eye must meet all ocular inclusion criteria, but none of the ocular exclusion criteria, to be eligible for unilateral dosing.

General All of the following criteria must be met for unilateral or bilateral dosing.

1. Age ≥ 5 years.
2. Genetically male patients with clinical diagnosis of XLRS caused by pathogenic or likely pathogenic mutations in RS1 OR Genetically female patients with clinical diagnosis of XLRS caused by biallelic pathogenic or likely pathogenic mutations in RS1.

   Ocular At least 1 eye must meet all of the following criteria for both unilateral and bilateral dosing.
3. BCVA of 34 to 73 ETDRS letters (corresponding to a Snellen acuity of 20/200 to 20/40).
4. Presence of foveal schisis on SD-OCT.

Exclusion Criteria:

General None of the following criteria can be met for unilateral or bilateral dosing.

1. Treatment with any carbonic anhydrase inhibitor (oral or topical) within 1 month prior to Screening.
2. Treatment in a prior ocular gene or cell therapy study.
3. Absence of macular schisis.
4. BCVA better than 75 ETDRS letters (corresponding to a Snellen acuity of 20/32).
5. Pre-existing eye conditions that would contribute significantly to an increased risk of visual loss from a subretinal injection (eg, advanced glaucoma, optic neuropathy, uveitis, corneal transplants).
6. Any intraocular surgery (including laser treatment) within 6 months prior to Screening or any intraocular surgery anticipated during the first 12 months of the study (laser treatment is allowed as long as it occurs at least 2 weeks before surgery).

Where it's running

• Associated Retina Consultants
  Phoenix, Arizona, United States Recruiting
• Children's Hospital of Los Angeles
  Los Angeles, California, United States Recruiting
• UC San Francisco
  San Francisco, California, United States Recruiting
• Bascom Palmer Eye Institute
  Miami, Florida, United States Recruiting
• Massachusetts Eye and Ear
  Boston, Massachusetts, United States Recruiting
• University of Michigan
  Ann Arbor, Michigan, United States Recruiting

Study contacts

• Study coordinator: Atsena Therapeutics Clinical Trials
• Email: clinicaltrials@atsenatx.com
• Phone: 984-261-2001

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Functional visual field and navigation testing for moderate-to-profound inherited retinal disease

  This project will test whether functional visual field and navigation tests can measure real-world vision and mobility in people with moderate-to-profound inherited retinal diseases.

  Recruiting Ray Therapeutics, Inc. · Irvine, California · NCT07502664

• Gene therapy for X-linked retinoschisis in children and adolescents

  This study is testing a new gene therapy for boys aged 5 to 18 with X-linked retinoschisis to see if it can improve their vision and eye health.

  Recruiting Early Phase 1 West China Hospital · Chengdu, Sichuan · NCT06345898

• Evaluating LX103 treatment for X-linked Retinoschisis

  This study tests if a new eye treatment called LX103 can improve vision in boys and men with X-linked Retinoschisis.

  Recruiting Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine · Shanghai · NCT05814952

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.